Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912574 · ClinicalTrials.gov registry record · NA
Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38
A NA study, sponsored by University of Virginia.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT00912574 is a NA study that has completed, run by University of Virginia. The registered enrollment target is 29 participants.
The verdict
NCT00912574, a NA study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
Goal: To characterize the cellular events that occur in vivo after vaccination with an emulsion of GMCSF-in-adjuvant. Design: Open-label, single dose study in two stages.
Interventions
- DRUG Saline
- DRUG Montanide ISA-51
- DRUG GM-CSF-in-adjuvant
- BIOLOGICAL GM-CSF and Montanide ISA-51
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2004-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00912574
The ClinicalTrials.gov registry entry for NCT00912574 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT00912574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00912574 about?
NCT00912574 is a clinical study titled "Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38". Goal: To characterize the cellular events that occur in vivo after vaccination with an emulsion of GMCSF-in-adjuvant. Design: Open-label, single dose study in two stages.
What is the current status of trial NCT00912574?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2004-06.
What interventions are being tested in trial NCT00912574?
The interventions under investigation include: Saline (DRUG), Montanide ISA-51 (DRUG), GM-CSF-in-adjuvant (DRUG), GM-CSF and Montanide ISA-51 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00912574?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.